And, you know, at the end of the day, it really comes down to the statutory limitation that the Board has in terms of adding new covered benefits that add a cost without having an offsetting cost savings. And To date, we haven't had sufficient data information provided to the Board that would essentially show us that there is cost savings that would be offset from the fairly significant additional cost from covering the GLP1s. So really, that's. That's where the decision comes down. You know, we'll continue to look at that as, you know, in, in future years as we have more information, and … (40:09–40:29)
CLAIM
Asserts that there is insufficient data to show cost savings from covering GLP1s.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
